Headquartered in New York, NY·Fiscal year ends December·NYSE: PFE·pfizer.com
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes medicines and vaccines worldwide.
**Business structure**
Nearly all revenue comes from its Global Biopharmaceuticals Business (Biopharma). Biopharma operates through three divisions:
- Pfizer U.S. Commercial Division
- Pfizer International Commercial Division
- Global Hospital and Biosimilars Division
**Product portfolios**
- **Primary Care:** Eliquis, the Prevnar family, Nurtec ODT/Vydura, Comirnaty, Abrysvo, Paxlovid and FSME-IMMUN/TicoVac.
- **Oncology:** Ibrance, Padcev, Xtandi, Lorbrena, Inlyta, Braftovi/Mektovi, Adcetris, Orgovyx, Tukysa, Bosulif, Elrexfio, Talzenna and Tivdak.
- **Specialty Care:** the Vyndaqel family, Xeljanz, Zavicefta, Enbrel, Octagam, BeneFIX, Cresemba, Genotropin and Cibinqo.
- **Hospital and Biosimilars (formed in 2026):** off-patent sterile injectables and biosimilars such as Retacrit, Ruxience, Zirabev, Inflectra and Sulperazon.
**Other operations and revenue sources**
- Pfizer CentreOne provides contract manufacturing and active pharmaceutical ingredient sales.
- Revenue comes from product sales, alliance revenues (e.g., Eliquis, Xtandi, Orgovyx) and royalties.
- The U.S. accounts for roughly two-thirds of sales.
**Strategy**
Pfizer is shifting away from declining COVID-19 products toward launched and acquired medicines, including those from the Seagen acquisition. It is investing in oncology, obesity, immunology and next-generation vaccine programs. It is also executing an enterprise-wide cost realignment and de-levering its balance sheet. Updated
Revenue by Segment · Q3 2026
Global Biopharmaceuticals Business98%
Pfizer CentreOne2%
Latest Activity
PodcastMad Money w/ Jim CramerJim Cramer · 44 min
Mad Money: Wall Street Jargon, Cyclicals, GARP & Corrections 11/13/26
Cramer defines cyclicals as economy-dependent: miners like BHP, autos, homebuilders, commodity chemicals
Secular growers are the recession-proof side: Procter & Gamble, General Mills, Pfizer, Merck, Eli Lilly
He flags GLP-1 drugs as the one threat to the eat-and-drink-forever staples thesis
Caller advice: 70% stocks even for older investors, and ease idle IRA cash in one-twelfth a month
The practical call is positioning: own more cyclicals when business is booming and lean on staples and drugmakers when growth rolls over. Cramer says sector membership now drives well over half of a stock's move thanks to sector ETFs, so being in the wrong camp costs you even when the company executes.
Pfizer is outrunning its COVID hangover: Paxlovid sales fell 63%, yet full-year revenue guidance rose to $62 billion to $64 billion. That is the seventh straight quarter of topping EPS expectations.
New 52-week high$30.52+0.3% vs prior high · 2026-10-22
Pfizer cleared $30 for the first time in a year, closing at $30.52 and topping its October 22 peak by 0.33%. The $173.9 billion drugmaker was trading near $23 twelve months ago.
New 52-week high$29.21+0.7% vs prior high · 2026-09-02
Pfizer hit a fresh 52-week high at $29.21, topping its September 2 peak. The drugmaker is now trading at levels no buyer from the past year is underwater on.
When a stock falls out of favor, the balance sheet decides what happens to your income. A company with manageable debt and steady cash flow can keep paying shareholders while it repairs…
A risk-free Treasury bill sounds hard to beat, yet three dividend payers in healthcare, tobacco, and pipelines offer more income. Each one also hides a risk that could turn a fat yield…
A double-digit yield can look like a steady paycheck, but it is only as reliable as the cash behind it. AGNC Investment (NASDAQ:AGNC) shows the risk. Its tangible net book value per…
A soaring yield can signal danger rather than a bargain. We tested five dividend payers against the same coverage and debt checks, and one household name in this group is already showing…
Retirees spend decades building a nest egg and then face a different problem: turning it into a paycheck that comes whether markets rise or fall. Part of the gap is covered by…
The JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) owns large U.S. stocks and sells call options against the market. The option premiums pay for a monthly check. Retirees have good reasons to own…
A fat yield looks like a gift until the cash behind it runs dry. Four household S&P 500 names are sending shareholders checks bigger than the money coming in, and one test…
At the 24% federal bracket, a $500,000 portfolio of four 6%-plus yielders produces about $31,114 a year in dividends and sends roughly $4,995 of it to the IRS if the holdings are…
Three famous dividend payers have lost a big chunk of their value since 2020, and two already slashed their payouts. Before chasing the fat yields, income investors should ask which of these…
Income investors tend to crowd into whatever is popular, leaving solid payers ignored. The three stocks below are in health care, telecom, and financials. Each pays at least 5%, and each has…
Retirees heading into year-end need income that holds up through a recession, a rate shift or a bad quarter, so a high yield alone isn’t enough. These five US-listed payers come from…
Conagra's falling stock price told one story while its board told another, and the board lost. Four more high-yield payers are sending the same mixed signals, and one cash flow line shows…
If you’re retired and living off a portfolio, a dividend has two jobs. It has to pay enough to matter, and it has to keep paying through a full market cycle. These…
At the 24% bracket, a $500,000 dividend portfolio making $33,000 a year sends $7,920 to the IRS every year when it sits in a taxable account. For tax year 2026, the 24%…
Two investors can own the same five blue chip dividend stocks and keep different amounts of income. When held outside a tax-advantaged account, every payment is taxed the year it arrives. With…
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes medicines and vaccines worldwide. **Business structure** Nearly all revenue comes from its Global Biopharmaceuticals Business (Biopharma). Biopharma operates through three divisions: - Pfizer U.S.
What is the PFE stock price target?
24/7 Wall St.'s 12-month price target for PFE is $33.48, rated Buy. The Wall Street consensus target is $30.22. PFE price prediction →